TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE by Elsone, L, Leite, M, Brown, R, McNeillis, B, Palace, J, Boggild, Jacob, M

New treatments and azathioprine in multiple sclerosis. by Palace, J, Rothwell, P

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES by Kitley, J, Elsone, L, George, J, Jacob, A, Leite, M, Palace, J

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis by Palace, J, Newsom-Davis, J, Lecky, B, Grp, M

“…We compared prednisolone (PRED) and azathioprine (AZA) versus prednisolone alone in the treatment of MG. …”

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies by Kitley, J, Elsone, L, George, J, Waters, P, Woodhall, M, Vincent, A, Jacob, A, Leite, M, Palace, J

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. by Kitley, J, Elsone, L, George, J, Waters, P, Woodhall, M, Vincent, A, Jacob, A, Leite, M, Palace, J

Is azathioprine effective in highly-active neuromyelitis optica? A multicentre study from the United Kingdom by Elsone, L, Kitley, J, Luppe, S, Lythgoe, D, Brown, R, McNeillis, B, Goh, Y, Mutch, K, Jacob, S, Leite, M, Robertson, N, Palace, J, Jacob, A

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. by Palace, J, Newsom-Davis, J, Lecky, B

“…We compared prednisolone (PRED) and azathioprine (AZA) versus prednisolone alone in the treatment of MG. …”

Long term efficacy, adherence and reasons for discontinuation in 103 cases of neuromyelitis optica treated with azathioprine: a multicentre study from the United Kingdom by Elsone, L, Kitley, J, Luppe, S, Lythgoe, D, Brown, R, McNeillis, B, Goh, Y, Mutch, K, Jacob, S, Leite, M, Robertson, N, Palace, J, Jacob, A

Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. by Elsone, L, Kitley, J, Luppe, S, Lythgoe, D, Mutch, K, Jacob, S, Brown, R, Moss, K, McNeillis, B, Goh, Y, Leite, M, Robertson, N, Palace, J, Jacob, A

“…BACKGROUND: Azathioprine (AZA) is a common immunosuppressive drug used for relapse prevention in neuromyelitis optica (NMO). …”

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. by Mealy, M, Wingerchuk, D, Palace, J, Greenberg, B, Levy, M

“…OBJECTIVE: To compare the relapse and treatment failure rates among patients receiving the 3 most common forms of immunosuppression for NMO: azathioprine, mycophenolate mofetil, and rituximab. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective, multicenter analysis of relapses in 90 patients with NMO and NMO spectrum disorder treated with azathioprine, mycophenolate, and/or rituximab at the Mayo Clinic and the Johns Hopkins Hospital during the past 10 years. …”

Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment. by Glennerster, A, Palace, J, Warburton, D, Oxbury, S, Newsom-Davis, J

“…We tested 11 patients with symptomatic MG at the start of a trial of immunosuppressive treatment (prednisolone plus azathioprine or placebo) and again when in remission. …”

Treatment of Neuromyelitis Optica: Review and Recommendations. by Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, de Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D

“…However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. …”

Treatment of neuromyelitis optica: Review and recommendations by Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Isabel Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, De Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D, Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository

“…However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. …”

Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease by Hacohen, Y, Wong, Y, Lechner, C, Jurynczyk, M, Wright, S, Konuskan, B, Kalser, J, Poulat, A, Maurey, H, Ganelin-Cohen, E, Wassmer, E, Hemingway, C, Forsyth, R, Hennes, E, Leite, M, Ciccarelli, O, Anlar, B, Hintzen, R, Marignier, R, Palace, J, Baumann, M, Rostásy, K, Neuteboom, R, Deiva, K, Lim, M

“…The median ARR was reduced from 1.84 to 1.0 with azathioprine (n = 20, P < .001), 1.79 to 0.52 with mycophenolate mofetil (n = 15, P = .003), and 2.12 to 0.67 with rituximab (n = 9, P < .001), although the median EDSS score remained unchanged. …”